Munch-a-Biotech Today Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: B O Trust who wrote (2830)	11/29/2009 1:51:52 PM
From: B O Trust	Read Replies (1) of 3158

CEO DIAMYD: "Diamyd is in the final stages with a number of potential partners for licensing of ongoing projects. More than that, I cannot say," said company CEO Elisabeth Lindner during Thursday's event. Diamyd's recent share issue were substantially oversubscribed. On December 11, 2009 the Annual General Meeting will decide on a share split 2:1, and raising the number of shares to between 18 up to 72 million shares as a preparation for what? Possibly IPO Nasdaq or another company munch. Diamyd have a minority share of Protein Sciences. financialhearings.eframe.se Diamyd® Diabetes Vaccine - Three Blockbuster Indications diamyd.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next